Median Technologies Announces Onboarding of All Academic Sites Involved in the Pivotal Validation Plan for iBiopsy® LCS CADe/CADx SaMD
Retrieved on:
Monday, July 17, 2023
Health Technology, Other Health, Technology, Radiology, Oncology, Biometrics, Medical Devices, Hospitals, Clinical Trials, Science, Biotechnology, Software, Other Science, Health, Research, CE marking, Medical device, CT, MT, CMS, University, Brag, Centers for Medicare & Medicaid Services, Intervention, LCS, Journal of Thoracic Oncology, Cancer, Lung cancer, University of Pennsylvania, Perelman School of Medicine at the University of Pennsylvania, Lung, Pulmonology, MD Anderson Cancer Center, Medicare, MD, Lalit Vachani, Patient, Clinical research, MRMC, University of Pennsylvania Health System, Diagnosis, Hospital of the University of Pennsylvania, AI, Mortality, Hospital, FDA, Respiratory Medicine, Disease, Pharmaceutical industry, Medical imaging
For the purposes of its pivotal validation plan, Median Technologies has signed clinical research agreements with world-class academic healthcare institutions, which are leading healthcare centers for the management of lung cancer patients.
Key Points:
- For the purposes of its pivotal validation plan, Median Technologies has signed clinical research agreements with world-class academic healthcare institutions, which are leading healthcare centers for the management of lung cancer patients.
- Median’s pivotal validation plan is composed of a pivotal standalone performance study (MT-LCS-002) and an international Multi-Reader Multi-Case (MRMC) pivotal clinical trial (MT-LCS-004).
- Data quality is compulsory for the proper conduct of our pivotal validation plan” said Fredrik Brag, CEO and Founder of Median Technologies.
- Now that we have onboarded all the sites, we are on track for the launch of our iBiopsy® LCS CADe/CADx SaMD pivotal validation plan.